126 results
Page 2 of 7
6-K
EX-99.1
9m8301zmyr7w 0q6c
18 Oct 22
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
7:07am
6-K
EX-99.1
m0kl3fx8 iwrksd1hbs6
17 Oct 22
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of
7:16am
6-K
EX-99.1
759rk
3 Oct 22
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
5:43pm
6-K
EX-99.1
cn1ox 09tp
26 Sep 22
Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by
7:18am
6-K
EX-99.1
55bv0lbsi08go7mtu
12 Sep 22
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
8:17am
6-K
EX-99.1
0tyvyz2 onmmb14w
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
6-K
EX-99.1
b9doqeli o8
22 Aug 22
Notifies Rubric of Certain Deficiencies in its Notice Purporting to Call a General Meeting of Shareholders
4:06pm
6-K
EX-99.1
emn4en c34iam6xb
5 Jul 22
Current report (foreign)
4:15pm
6-K
EX-99.1
g4m 2kdity9
2 Jun 22
Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan
9:07am
6-K
EX-99.1
obaq2xgc2l51
26 May 22
Current report (foreign)
5:11pm
6-K
EX-99.1
o9g285zulgg qxu2
17 May 22
Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors
8:19am
6-K
EX-99.1
tuqbrhw
9 May 22
Current report (foreign)
8:06am
6-K
sqttwnna
9 May 22
Current report (foreign)
8:06am